Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results
Date:
8/10/17
Longer follow-up results from using the first coformulated injectable ART were presented from the phase 2b LATTE study. [1]
Following a lead period that included using oral formulations of cabotegravir and rilpivirine, 286 treatment-naive participants were randomised (2:2:1) to either 8-weekly (8W) or 4-weekly (4W) injections, or to oral cabotegravir plus abacavir/3TC.